DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | AliX | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | BioMedical Diagnostics | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-modeling) | BT Pharma | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | Cezanne | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Exonhit | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences (AbAg) | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | Magnisense | Mapreg | MAT Biopharma | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | Novagali | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma (ex-Nova Decision) | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharmaxon | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sepal Pharma | Serial Genetics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UroGene | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* ALIZÉ PHARMA *

 

2007 - Rhône-Alpes
Ecully
(near Lyon)
www.alz-pharma.com

 

Discovery, Drugs
Key words: Diabetes, Leukaemia, Recombinant L-asparaginase
Mission: to develop innovative therapeutics for the treatment of metabolic diseases and cancers (after early acquisition of products from Biotechs and in-house preliminary development)
Clients: Pharmaceutical industry
contact@alz-pharma.com

Age: 4 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: Abribat (Thierry) [co-founder, born 1964, Ph.D., Vet.D., ex-Sanofi-Recherche, Theratechnologies, OPi (CEO)]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev: Delale (Thomas)
Financers (Hist.): Octalfa (Gilles Alberici, board member), CEMA (Canada, André de Villers, board member), SHAM (registered capital 2007 = 0.052 M€)

Turnover (M€) : 0.063 (2009)
Total funding (M€) : 4.8
Last funding (M€) : 3.0
Focus : Multiple
Position : Preclin
Company confirm : none

 

History
DATEMILESTONETYPETIME
2010 .01 Partnering R&D agreement with Eli Lilly (USA) on unacylated ghrelin (AZP-01) program for the treatment of type II diabetes (with licence option) R&D [2 years]
2009 .09 1st round-financing : 3.0 M€, by SHAM and previous investors RFINA [2 years]
2008 .05 Licensing-in of preclinical recombinant L-asparaginase program for the treatment of acute lymphoblastic leukaemia, a lead compound from EUSA Pharma (USA) LICIN [1 year]
2007 .09 Seed financing : 0.7 M€, by 2 private companies, Octalfa (Gilles Alberici), CEMA (Canada, André de Villers) SFIN [0 year]
2007 .04 Company founded by Thierry Abribat and André de Villers [co-financer, M.D., ex-Theratechnologies] ORGF [0 year]

Actualisation / Updating: 3-May-2011

   

Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2011. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende